Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according ...

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose ...

Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena administered via the CirCLIQ® on-body injector (OBI) offers a ...

Patients with mild cognitive impairment or mild dementia due to Alzheimer's can now begin treatment with a subcutaneous ...

Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...

Sanofi announced that US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients ...

The FDA has approved a subcutaneous version of isatuximab (Sarclisa Escena, Sanofi-Aventis) for several multiple myeloma (MM) ...

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

COMMENT: Needle-free weight loss has arrived in the UK, prompting a surge of interest from pharmacy customers. But after ...

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International Conference ® (AAIC ®) 2026 in London support that the LEQEMBI ® ...

Testosterone replacement therapy (TRT) can improve energy, mood, and libido but the delivery method you choose has a major impact on cost, convenience, and side effects.

The percentage of American adults who are currently taking a GLP-1 drug for weight loss is 11%, according to a new survey ...